New drug combo aims to boost lymphoma remission in patients with key mutations
NCT ID NCT06846463
First seen Feb 02, 2026 · Last updated May 20, 2026 · Updated 22 times
Summary
This study tests whether adding the oral drug zanubrutinib to standard chemotherapy (R-CHOP) helps more people with diffuse large B-cell lymphoma (DLBCL) achieve complete remission. It is for patients whose tumors have certain genetic changes (MYD88, CD79B, NOTCH1 mutations or CD5 positivity). About 21 adults will take zanubrutinib pills alongside R-CHOP, and researchers will track how many have no cancer signs after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.